1. Microbiota's Effects
1.1. Drug Pharmaceuticals
1.2. Anti-Cancer Treatments
1.3. Drug Toxicity
2. Functions
2.1. Reinforcement
2.2. Skin Repair
2.3. Defenses against Infection
2.4. Tight Cell Contacts
2.5. Cross-Talk between other Organ Systems
3. Immune System
3.1. Training
3.2. Support
4. Microbial Colonization
4.1. Lifestyle Factors
4.2. Systemic Host Factors
4.3. Environmental Factors
4.4. Local Host Factors
4.5. Barriers
4.5.1. Microbial Barrier
4.5.2. Physical Barrier
4.5.3. Immune Barrier
4.5.4. Chemical Barrier
4.6. Microbiota Sequencing
4.6.1. Amplification
4.6.2. Shotgun Genome Metagenomics
4.6.3. Cross-Talk
4.6.3.1. Skin Commentals
4.6.3.2. Stalpylococcus Aureus
4.7. Human Metabolism/Metabolic Diseases
4.7.1. Immune Hypersensitivity Disorders
4.7.1.1. Eczema
4.7.1.2. Skin Allergies
4.7.1.3. Chronic Wounds
4.7.1.4. Cane
4.7.2. Engineered Skin Bacteria
4.7.2.1. Induced Anti Tumour
4.7.2.1.1. T-Cell Responses
4.7.3. Itching of Skin
4.7.3.1. Staphylococcus Aureus
4.7.3.2. Protease V8
4.7.3.3. PAR-1
4.7.3.3.1. Vorapaxar
4.7.4. mEnrich-Seq
4.7.4.1. Economic Approach
4.7.4.1.1. Microbiome Research
4.7.4.2. Focus on Wide Range of Bacteria
4.7.4.3. Accelerated Development
4.7.4.3.1. New Diagnostic Tools
4.7.4.3.2. New Treatments
5. Skin Microbiome
5.1. Functions
5.1.1. Reinforces Skin
5.1.2. Repairs Skin
5.1.3. Defense
5.1.3.1. Infections
5.1.3.2. Ecess Inflammation
5.1.4. Reinforcement
5.1.4.1. Cell Adhesion
5.1.4.1.1. Tight Junctions
5.1.5. Cross-Talk
5.1.5.1. Other Organs
5.2. Immune System
5.2.1. Training
5.2.2. Support
5.3. Microbial Colonization
5.3.1. Factors
5.3.1.1. Lifestyle
5.3.1.2. Systemic
5.3.1.3. Environmental
5.3.1.4. Local Host
5.4. Barriers
5.4.1. Microbial
5.4.2. Physical
5.4.3. Immune
5.4.4. Chemical
5.5. Micrbiota Sequencing
5.5.1. Amplification
5.5.2. Whole Genome Metagenomics
5.6. Cross-Talk
5.6.1. Skin Commensals
5.6.1.1. Staphylococcus Aureus
5.7. Immune Hypersensitivity Disorders
5.7.1. Ezcema
5.7.2. Skin Allergies
5.7.3. Chronic Wounds
5.7.4. Acne
5.8. Engineered Skin Bacteria
6. Biological Self
6.1. Classical Explination
6.1.1. Genetics
6.1.2. Physiological Changes
6.1.3. Environmental Factors
6.2. Host Microbial Relationship
6.2.1. Hygiene Hypothesis
6.2.2. Microbiome Analysis
6.2.3. Microbial Diversity Loss
6.2.4. Benefits
6.2.4.1. Metabolizing Nurtients
6.2.4.2. Producing VItamins
6.2.4.3. Shaping Immune System
6.2.4.4. Maintaining Gut Barrier Integrity
6.2.5. Dysbiosis and Disease
6.2.5.1. Infection Diseases
6.2.5.2. Microbial Imbalance
6.2.5.3. COVID-19 Impact
6.2.6. Gut-Brain Axis
6.2.6.1. Communication
6.2.6.1.1. Pathways
6.2.6.1.2. Behaviour Effects
6.2.7. Gut Health Benefits
6.2.7.1. Developement and Diversity
6.2.7.1.1. Early-Life Nutrition
6.2.7.1.2. Microbial Colonization
6.2.7.1.3. Nutrition
6.2.8. Colonization Resistance
6.2.8.1. Mechanisms
6.2.8.1.1. Competition
7. PV-1
7.1. Biomarker
7.1.1. Used for Diagnostics
8. CRC
8.1. High PV-1
8.1.1. Liver
9. Bacteria
9.1. Intracellular Bacteria
9.1.1. Actin Cytoskeleton reorganization
9.1.1.1. CTCs
9.1.2. CTC Survival
9.1.2.1. Resistance to Mechanical Stress
9.2. E.Coli 17
9.2.1. GVP Impairment
9.2.2. PMN Maturation
10. Microbiota Modulation
10.1. Gut Microbiome Modules
10.1.1. Liver Metassis
10.1.1.1. Bile Acid
10.2. Chemotherapy
10.3. Radiotherapy
10.4. Immunotherapy
11. Strategies to Target Microbiota
11.1. PD-1 Blockade
11.1.1. Fecal Microbiota Transplantation (FMT)
11.1.2. Probiotic -Guided CAR-T Cells (ProCARS)
11.2. Gut-Targeted Drugs
11.2.1. Metabolic Diseases
11.3. Bone Marrow Transplantations
12. Clincal Applications
12.1. Goal of FMT
12.1.1. Change Microbitoa
12.1.1.1. Weak
12.1.1.2. Strong
12.2. Drugs
12.2.1. Rebyota
12.2.1.1. First Human Stool Therapy
12.2.1.1.1. Administered Through Enema
12.2.2. SER-109
12.2.2.1. Administered Orally
12.2.3. Treatment for Autism
12.2.3.1. FMT for Autism
12.2.3.1.1. Drugs
12.3. Biofilms
12.3.1. Adhesion
12.3.2. Bioavailability
12.3.3. Programmable Probiotics
12.3.4. Inflammation Relief
12.3.5. Microbial Communities
12.4. Specific Microbial Signatures
12.4.1. Machine Learning
12.4.2. Artificial Intelligence
12.4.2.1. Diagnostics
12.4.2.1.1. Early Detection for Diseases
12.4.3. Modulation of Human Microbiome
12.4.3.1. Ve800
12.4.3.2. Ve303
12.4.3.3. Ve416
12.4.3.4. Ve202
12.4.3.5. Prevention
12.4.3.5.1. CDI
12.4.3.5.2. Food Allergy
12.4.3.5.3. IBD
12.4.3.6. Live Micrboial Biotherapeutic Products
12.4.3.7. Oncomimic-Based Immunotherapy
12.4.3.7.1. Pepetides
13. Historical Context
13.1. Development of Instruments
13.1.1. Microscope